New Delhi, Oct 23 (UNI) Pharmaceutical firm Suven Life Sciences Ltd today said it has received three product patents from Indian Patent Office (IPO) for new chemical entities (NCEs) for the treatment of Neuro degenerative diseases.
The patents granted by the IPO are valid until 2022, company said in a statement.
The granted claims of the patents include selective 5-HT compounds discovered by the company, which are being developed as therapeutic agents, are useful in the treatment of disorders like alzhemier's, attention deficient hyperactivity, huntington's, parkinson and schizophrenia, it added.
The company so far has filed 25 product patents out of which 10 has entered national phase. These are the first product patents granted to the company from its four years of drug discovery efforts, the statement said.